Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 357 in Rheumatoid Arthritis
NCT02499315Phase 1Terminated
- Sponsor
- Amgen
- Start
- Apr 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing AMG 357 with Placebo (2 arms). Primary endpoint: Number of subjects reporting treatment-emergent adverse events at 1 year. Started Apr 2015; status: terminated.
02
Drugs
AMG 357
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02499315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02499315.